At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 14 enrolled

Drug / intervention

escitalopram +1 moredrug

Likely dose

Escitalopram: 10 mg/day for 1 week, then 20 mg/day for 7 weeks (open-label phase); 20 mg/day (double-blind phase)AI-extracted

Key inclusion· 2

✓Confirmed diagnosis of OCD
✓Yale Brown Obsessive-Compulsive Scale (YBOCS) score ≥16 at both screening and baseline visits

Key exclusion· 10

✕Lifetime history of psychosis or cognitive dysfunction secondary to general medical condition or substance use
✕Primary diagnosis of another Axis I psychiatric disorder
✕Alcohol or substance abuse/dependence within the past 6 months
✕Unstable medical condition

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00215137

NCT00215137Phase 2Completed

Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder

Duke University·interventional·Posted Sep 22, 2005·Updated Jul 23, 2014

In Brief

A Phase 2 clinical trial evaluating escitalopram and Placebo ( sugar pill) for OCD. Completed, enrolled 14 participants across 1 site.

This study will determine the safety and effectiveness of escitalopram (Lexapro)in treating obsessive-compulsive disorder (OCD) symptoms.

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsOCD

CountriesUnited States

Phase 2CompletedFinished

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartOct 2004

First PostedSep 2005

Primary CompletionJan 2009

Study CompletionMar 2009

TodayJul 2026

First PostedSep 22, 2005

Enrollment StartOct 1, 2004

Primary CompletionJan 1, 2009

Study CompletionMar 1, 2009

TodayJul 2, 2026

Enrollment to primary: 4.3 yearsPosted 20.8 years ago

escitalopramdrug

Open label Treatment: Escitalopram 10 mg/day for 1 week and then 20 mg /day for 7 weeks. Double Blind Treatment: Escitalopram 20 mg/day.

Placebo ( sugar pill)drug

Placebo Comparator in double.blind phase.